» Articles » PMID: 12874201

The Immune Response Modifier and Toll-like Receptor 7 Agonist S-27609 Selectively Induces IL-12 and TNF-alpha Production in CD11c+CD11b+CD8- Dendritic Cells

Overview
Journal J Immunol
Date 2003 Jul 23
PMID 12874201
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

IL-12 and TNF-alpha production by dendritic cells (DCs) is a critical step in the initiation of local inflammation and adaptive immune responses. We show in this study that a small molecule immune response modifier that is a Toll-like receptor 7 (TLR7) agonist induces IL-12 and TNF-alpha production from murine CD11c(+)CD11b(+)CD8(-) DCs, a subset not previously known for this activity. Stimulation of these DCs through TLR7 in vivo induces significant cytokine production even 12 h after initial stimulation, as well as migration of the DC into T cell zones of the lymphoid tissue. In contrast, stimulation through TLR4 and TLR9 induced IL-12 production predominantly from CD8(+) DCs, consistent with previously published data. All TLR stimuli induced the increase in surface expression of the activation markers B7-1, B7-2, and class II in both CD8(+) and CD8(-) DCs, demonstrating that CD8(+) DCs do respond to TLR7-mediated stimuli. To date this is the only known stimuli to induce preferential cytokine production from CD8(-) DCs. Given the efficacy of TLR7 agonists as antiviral agents, the data collectively indicate that stimulation of CD8(-) DCs through TLR7 most likely plays a role in the generation of antiviral immune responses.

Citing Articles

Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells.

Sanlorenzo M, Novoszel P, Vujic I, Gastaldi T, Hammer M, Fari O Nat Cancer. 2025; 6(1):175-193.

PMID: 39849091 PMC: 11779648. DOI: 10.1038/s43018-024-00889-9.


An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.

Jensen S, Jaehger D, Serrano-Chavez E, Halldorsdottir H, Engel T, Jorgensen J Nat Commun. 2024; 15(1):7687.

PMID: 39227589 PMC: 11371921. DOI: 10.1038/s41467-024-50967-w.


Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer.

Alsaiari S, Nadeef S, Daristotle J, Rothwell W, Du B, Garcia J Sci Adv. 2024; 10(10):eadj6380.

PMID: 38446889 PMC: 10917347. DOI: 10.1126/sciadv.adj6380.


Structural Optimization and Biological Evaluation of Isoxazolo[5,4]pyrimidines as Selective Toll-Like Receptor 7 Agonists.

Strasek Benedik N, Dolsak A, Svajger U, Sosic I, Gobec S, Sova M ACS Omega. 2024; 9(2):2362-2382.

PMID: 38250345 PMC: 10795023. DOI: 10.1021/acsomega.3c06343.


The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview.

Veneziani I, Alicata C, Moretta L, Maggi E Biomedicines. 2023; 11(1).

PMID: 36672572 PMC: 9855813. DOI: 10.3390/biomedicines11010064.